Main Inclusion Criteria:
* Male or female aged 18 and 65 years inclusive
* Confirmed diagnosis of WD
* Treated for WD according to international recommendations with no current evidence for inadequate treatment
* Stable WD for ≥ 1 year, defined as: (i) No significant change in neurologic examination and in status of mood disorder and (ii) Stable laboratory parameters used to assess copper metabolism
Main Exclusion Criteria:
* ALT level ≥ 2 ULN that is not readily explained by extrinsic factors
* Total bilirubin \> 1.5 x ULN in the absence of proven Gilbert's syndrome; in case of Gilbert's syndrome, direct bilirubin \> ULN
* INR \> 1.2
* Any signs of liver cirrhosis decompensation, including gastrointestinal bleed within 6 months (24 weeks) prior to screening/enrollment visit
* Patient has moderate or severe renal impairment defined as eGFR CKD-EPI \< 60 mL/min/1.73 m2, or patient has nephritis or nephrotic syndrome
* Any history or current evidence of HIV-1, HIV-2, HTLV 1, or HTLV-2 infection
* Any history or current evidence of hepatitis B infection
* Any history of hepatitis C infection, unless previous viral RNA assays in two samples, collected at least 6 months apart, are negative
* Positive QuantiFERON®-TB Gold tuberculosis test result
* Any concomitant disorder/condition - including hepatic disorders - or treatment possibly interfering with the conduct or evaluation of the study
* Any history of diabetes
* Pregnancy or breastfeeding
* Body Mass Index ≥ 35 kg/m2
Other protocol defined Inclusion/ Exclusion criteria may apply
View Inclusion and Exclusion Criteria at ClinicalTrials.gov